Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $90.1 million.

  • Denali Therapeutics' Total Current Liabilities rose 350.54% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 350.54%. This contributed to the annual value of $102.2 million for FY2024, which is 3106.61% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Total Current Liabilities is $90.1 million, which was up 350.54% from $91.1 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Total Current Liabilities ranged from a high of $391.1 million in Q1 2023 and a low of $51.4 million during Q2 2021
  • Its 5-year average for Total Current Liabilities is $167.5 million, with a median of $90.1 million in 2025.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 57719.6% in 2022, then tumbled by 8026.45% in 2023.
  • Quarter analysis of 5 years shows Denali Therapeutics' Total Current Liabilities stood at $378.2 million in 2021, then fell by 3.79% to $363.9 million in 2022, then crashed by 78.57% to $78.0 million in 2023, then soared by 31.07% to $102.2 million in 2024, then fell by 11.8% to $90.1 million in 2025.
  • Its last three reported values are $90.1 million in Q3 2025, $91.1 million for Q2 2025, and $91.9 million during Q1 2025.